The bacterium, called Pseudomonas aeruginosa, is the most common cause of persistent and fatal lung infections in cystic fibrosis patients. Scientists at Liverpool identified a particularly virulent strain of the bacteria that is transmissible between patients. The Liverpool Epidemic Strain (LES), referred to as a cystic fibrosis 'superbug', can cause aggressive infection and results in progressive lung decline.
The team from the University's Institute of Infection and Global Health took samples from patient sputum and cough swabs to understand why the infection is so aggressive in people with cystic fibrosis. They found that during chronic infections the bacteria has the ability to mutate rapidly, resulting in huge diversity. Tests also show that the bacteria produce a molecule that could be the trigger for episodes of acute infection in patients.
Dr Craig Winstanley, member of the National Institute of Health Research (NIHR) Biomedical Research Centre (BRC) at Liverpool, explains: "Patients with LES need to be separated from others in hospitals, so that infection does not spread between cystic fibrosis patients on wards. Once established, these chronic infections can never be cleared. We found that the bacteria have the ability to diversify into hundreds of distinct sub-types, making it very difficult to decide which antibiotic to use for a successful outcome.
"Using the latest DNA technology we have the unique opportunity to study the behaviour of bacteria during chronic infection in real time. This will allow us to get a clearer picture of how it adapts so efficiently to cystic fibrosis patients. If we can understand how and why it behaves the way that it does we may be able to target more effective treatments for the infection."
Working with scientists at the University's Centre for Genomic Research, the team will use new DNA sequencing technology to read the genetic code of the infection. The first of its kind in the UK, the machine works 250,000 times faster than technology used to sequence the human genome 10 years ago.
Dr Steve Paterson, from the University's Institute of Integrative Biology, said: "Each cystic fibrosis patient can be infected with a diverse population of bacteria and it is therefore essential to test samples of the disease from a number of patients in order to understand how it evolves. The technology we are using can read 30 billion letters of DNA sequence per day, compared to four billion using current machines. It will allow us to investigate the mutations of the infection in precise detail, giving us valuable information about the progress of this serious medical condition."
The research is funded by the Wellcome Trust.
Notes to editors:
1. The research follows a University study on Pseudomonas aeruginosa published in the American Journal of Respiratory and Critical Care Medicine. The work, in collaboration with Dr Martin Walshaw from the Liverpool Heart and Chest Hospital, was supported by the Dr Hadwen Trust and the NIHR through the Liverpool Biomedical Research Centre.
2. The Wellcome Trust is a global charitable foundation dedicated to achieving extraordinary improvements in human and animal health. It supports the brightest minds in biomedical research and the medical humanities. The Trust's breadth of support includes public engagement, education and the application of research to improve health. It is independent of both political and commercial interests. www.wellcome.ac.uk
3. The NIHR Biomedical Research Centre (BRC) in Liverpool is one of 12 in the country and is funded by the National Institute for Health Research (NIHR) and the North West Development Agency (NWDA). It is run jointly by the University of Liverpool, the Royal Liverpool and Broadgreen University Hospitals Trust and the Liverpool School of Tropical Medicine. The Centre focuses on four areas of microbial disease - hospital and community acquired infections, chest infections, sexual health, and safety of antimicrobial drugs.
4. The NIHR provides the framework through which the research staff and research infrastructure of the NHS in England is positioned, maintained and managed as a national research facility. The NIHR provides the NHS with the support and infrastructure it needs to conduct first class research funded by the Government and its partners alongside high-quality patient care, education and training. Its aim is to support outstanding individuals (both leaders and collaborators), working in world class facilities (both NHS and university) and, conducting leading-edge research focused on the needs of patients. www.nihr.ac.uk
5. The University of Liverpool is a member of the Russell Group of leading research-intensive institutions in the UK. It attracts collaborative and contract research commissions from a wide range of national and international organisations valued at more than £110 million annually.